Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
With a big stake in hand, Samantha Du files for $115M IPO for Zai Lab
8 years ago
Financing
China
Bristol-Myers shares sink after another setback for its immuno-oncology franchise drugs
8 years ago
R&D
As Trump lashes out at Frazier again, J&J's Alex Gorsky says he's not abandoning president's council
8 years ago
Pharma
Biosims making slow progress battling blockbusters for market share; FibroGen raising $300M
8 years ago
News Briefing
Drug developers face increasingly risky tightrope walk between top-line results and hard data
8 years ago
R&D
With an eye on the FDA, Lexicon and Sanofi line up more positive data on diabetes drug
8 years ago
R&D
What's worth $500M-plus? The Big 6 deals of Q2 show you where the money is — and isn't
8 years ago
Pharma
Is Amazon planning to disrupt the $560B prescription drug market?
8 years ago
Pharma
Trump's renewed broadsides on drug pricing didn't even dent biopharma this time
8 years ago
Bioregnum
Opinion
J&J beefs up neuro pipeline, bags a new depression drug from Cerecor in $45M deal
8 years ago
Pharma
Cel-Sci shares jump after FDA lifts hold; New upstart is looking for Euro marketing pacts with biotech
8 years ago
News Briefing
In a rare misfire, Regeneron scraps its RSV drug after a PhIII failure
8 years ago
R&D
Merck CEO Ken Frazier resigns from Trump council in protest, and the president swiftly bites back
8 years ago
Pharma
Zynerba shares crushed (again) as back-to-back flops leave lead drug under a cloud
8 years ago
R&D
Focused on data and drug development, SoftBank hunts new $1B biotech deals — report
8 years ago
Pharma
Mundipharma picks up a PhIII-ready chemo creation in $250M deal
8 years ago
Pharma
Novartis partner Ophthotech says wet-AMD drug Fovista goes 0-for-3 in PhIII
8 years ago
R&D
Novartis veteran David Epstein takes leadership role at Rubius
8 years ago
Peer Review
Here's why Sucampo paid $200M for its PhIII Niemann-Pick drug
8 years ago
R&D
Peregrine slashes R&D in a reorg that claims 60 jobs; Zai Labs in hunt for $150M IPO - report
8 years ago
News Briefing
GSK abandons Ionis' FDA-ready inotersen as new CEO sweeps out rare disease efforts
8 years ago
Pharma
Dicerna escalates war with Alnylam over RNAi secrets, claiming its rival wants a monopoly
8 years ago
Pharma
Gilead circles February 12 on its calendar as D-day for its HIV franchise
8 years ago
Pharma
Gushing red ink, biotech billionaire Soon-Shiong slashes staff at NantHealth by 300, sells assets
8 years ago
People
R&D
First page
Previous page
1091
1092
1093
1094
1095
1096
1097
Next page
Last page